# Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

Source: https://onco.cc/trials/nct02697734/  
OnCo record `nct02697734` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Osilodrostat in Pituitary tumours, run by Novartis Pharmaceuticals, completed.

## Summary

Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease is a phase 3 interventional study registered as NCT02697734 by Novartis Pharmaceuticals, with 73 participants recorded, started 2016-10-03 and reaching its primary completion in 2019-06-19. Interventions recorded: osilodrostat, osilodrostat Placebo. Conditions recorded: Cushing's Disease.

Linked to the drug Osilodrostat because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02697734
- Phase: 3
- Setting: A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 73

## Sources

- ClinicalTrials.gov NCT02697734: https://clinicaltrials.gov/study/NCT02697734

## Connected records

- cancers: [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/)
- drugs: [Osilodrostat](https://onco.cc/drugs/osilodrostat/)

---
JSON: https://onco.cc/api/v1/entities/nct02697734.json